Navidea Biopharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.06.19	6 Top Gainers In Pharma Sector (MRTX, NK, GNCA...) (RTTNews)
19.04.19	Navidea Biopharmaceuticals Announces Reverse Stock Split (Businesswire)
08.04.19	Navidea Biopharmaceuticals Receives FDA Feedback Regarding Rheumatoid Arthritis Clinical Trial Design and Provides Business Updates (Businesswire)
02.04.19	Navidea Biopharmaceuticals Data to be Presented at Society of Nuclear Medicine and Molecular Imaging Annual Meeting (Businesswire)
22.03.19	Navidea Biopharmaceuticals Announces Stock Purchase Agreement; Other Business Updates (Businesswire)
07.03.19	Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results (Businesswire)
28.02.19	Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update (Businesswire)
01.02.19	Navidea Biopharmaceuticals Announces Extension of NYSE American Listing (Businesswire)
24.01.19	Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court (Businesswire)
07.12.18	Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek® (Businesswire)
29.11.18	Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors (Businesswire)
29.11.18	Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer (Businesswire)
28.11.18	Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018 (Businesswire)
27.11.18	Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018 (Businesswire)
26.11.18	Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors (Businesswire)
07.11.18	Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results (Businesswire)
01.11.18	Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update (Businesswire)
31.10.18	Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation (Businesswire)
30.10.18	Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American (Businesswire)
11.10.18	Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting (Businesswire)
08.10.18	Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum (Businesswire)
17.09.18	Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program (Businesswire)
17.09.18	Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement (Businesswire)
17.08.18	Navidea Biopharmaceuticals Announces Results of the Annual Shareholder Meeting (Businesswire)
16.08.18	Navidea Biopharmaceuticals Announces Details of 2018 Annual General Meeting (Businesswire)
15.08.18	Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American (Businesswire)
09.08.18	Navidea Biopharmaceuticals Reports Second Quarter 2018 Financial Results (Businesswire)
12.07.18	Navidea Management to Host Moderated Q&A Webcast to Provide Corporate Update (Businesswire)
14.06.18	Navidea to Host Moderated Q&A Webcast with Management (Businesswire)
30.05.18	Navidea Biopharmaceuticals to Present at 8th Annual LD Micro Invitational Conference and Participate in the 2018 BIO International Convention (Businesswire)
08.05.18	Navidea Biopharmaceuticals Reports First Quarter 2018 Financial Results (Businesswire)
02.05.18	Navidea Biopharmaceuticals Schedules First Quarter 2018 Earnings Conference Call and Business Update (Businesswire)
16.04.18	Navidea Biopharmaceuticals to Present at 2nd Annual NASH Summit (Businesswire)
16.04.18	Navidea Signs Deal to Sublicense NAV4694 Worldwide Development Rights (Businesswire)
03.04.18	Navidea Biopharmaceuticals Schedules Conference Call to Discuss Future Outlook and Outcomes of Court Trial (Businesswire)
15.03.18	Navidea Biopharmaceuticals to Present at 25th Annual Future Leaders in the Biotech Industry (Businesswire)
08.03.18	Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results (Businesswire)
28.02.18	Navidea Biopharmaceuticals Schedules Fourth Quarter and Full Year 2017 Earnings Conference Call and Business Update (Businesswire)
01.02.18	Navidea to Host Moderated Q&A Webcast with Management (Businesswire)
19.12.17	Navidea Biopharmaceuticals to Present at Biotech Showcase 2018 (Businesswire)
21.11.17	Navidea Biopharmaceuticals to Present at LD Micro 10th Annual Main Event (Businesswire)
07.11.17	Navidea Biopharmaceuticals Reports Third Quarter 2017 Financial Results (Businesswire)
01.11.17	Navidea to Present Late-Breaking Abstract at American College of Rheumatology Annual Meeting (Businesswire)
31.10.17	Navidea Biopharmaceuticals Schedules Third Quarter 2017 Earnings Conference Call and Business Update (Businesswire)
27.10.17	Navidea Signs Letter of Intent to Sublicense NAV4694 Worldwide Development Rights (Businesswire)
19.07.17	Today's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea Biopharma, and Biostage (PR Newswire)
16.06.17	Daily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma (PR Newswire)
12.06.17	Navidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® in Europe (Businesswire)
09.05.17	Biotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Navidea Biopharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten